Fortrea Previews J.P. Morgan Healthcare Conference Updates
DURHAM, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today previewed […]
Relay Therapeutics Announces $30 Million Private Placement Financing
CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the […]
First Watch to Acquire 21 Franchise Restaurants in North Carolina
Transaction Represents Acquisition of Largest Franchisee Amends Credit Agreement to Support Acquisitive Growth BRADENTON, Fla., Jan. 08, 2024 (GLOBE […]
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted […]
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on […]
CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative […]
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
AUSTIN, TX and DURHAM, NC, Jan. 08, 2024 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology […]
R1 RCM Announces Preliminary Fourth Quarter Results
R1 RCM expects fourth quarter revenue of approximately $563 to $567 million, GAAP Operating income of $36 to $39 million, […]
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful […]
Travere Therapeutics Provides Corporate Update and 2024 Outlook
Received 459 new patient start forms for FILSPARI®(sparsentan) in the fourth quarter of 2023; preliminary net product sales of FILSPARI […]
